Disease · MONDO_0005542
Comparisons in its trials64
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 64
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ezetimide/Simvastatin vs Simvastatin: serious adverse events | 3,640 of 9,067 | 3,649 of 9,077 | 18,144 | NCT00202878 | Trial comparisons |
Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events | 797 of 6,813 | 938 of 6,795 | 13,608 | NCT00097591 | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke | 692 of 6,813 | 822 of 6,795 | 13,608 | NCT00097591 | Trial comparisons |
| Prasugrel vs Clopidogrel: serious adverse events | 1,731 of 6,741 | 1,675 of 6,716 | 13,457 | NCT00097591 | Trial comparisons |
| Eptifibatide vs Placebo: serious adverse events | 66 of 4,686 | 60 of 4,643 | 9,329 | NCT00089895 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding | 19 of 4,374 | 14 of 4,365 | 8,739 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of GUSTO Severe / Life-threatening Bleeding | 10 of 4,374 | 11 of 4,365 | 8,739 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of ACUITY Major Bleeding | 151 of 4,374 | 120 of 4,365 | 8,739 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of ACUITY Major Bleeding (Without Hematoma >/= 5 cm) | 78 of 4,374 | 65 of 4,365 | 8,739 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: serious adverse events | 125 of 4,374 | 127 of 4,365 | 8,739 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, or Unsuccessful Procedure During the Index PCI | 127 of 3,897 | 141 of 3,871 | 7,768 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR) | 290 of 3,889 | 276 of 3,865 | 7,754 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Individual Incidence of All-cause Mortality | 8 of 3,889 | 5 of 3,865 | 7,754 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality and MI | 285 of 3,889 | 261 of 3,865 | 7,754 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Individual Incidence of IDR | 13 of 3,889 | 23 of 3,865 | 7,754 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality, MI or IDR | 343 of 3,860 | 327 of 3,827 | 7,687 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of Stroke | 5 of 3,860 | 7 of 3,827 | 7,687 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality | 34 of 3,860 | 29 of 3,827 | 7,687 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of IDR | 44 of 3,860 | 52 of 3,827 | 7,687 | NCT00305162 | Trial comparisons |
| Cangrelor Arm vs Clopidogrel Arm: Incidence of All-cause Mortality or MI | 321 of 3,860 | 298 of 3,827 | 7,687 | NCT00305162 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005542/comparisons